dc.contributor.author | ULUTİN, TURGUT | |
dc.date.accessioned | 2021-03-05T19:47:24Z | |
dc.date.available | 2021-03-05T19:47:24Z | |
dc.date.issued | 2008 | |
dc.identifier.citation | ULUTİN T., "VKORC1 and CYP2C9 polymorphisms are associated with warfarin dose requirements in Turkish patients.", Eur J Clin Pharmacol., cilt.64, ss.889-894, 2008 | |
dc.identifier.other | vv_1032021 | |
dc.identifier.other | av_d0ecfa86-664d-4862-8016-7db56b0fe40d | |
dc.identifier.uri | http://hdl.handle.net/20.500.12627/138110 | |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/pubmed/18542936 | |
dc.language.iso | eng | |
dc.subject | Temel Bilimler | |
dc.subject | Moleküler Biyoloji ve Genetik | |
dc.subject | Yaşam Bilimleri | |
dc.subject | Moleküler Biyoloji ve Genetik | |
dc.subject | Yaşam Bilimleri (LIFE) | |
dc.title | VKORC1 and CYP2C9 polymorphisms are associated with warfarin dose requirements in Turkish patients. | |
dc.type | Makale | |
dc.relation.journal | Eur J Clin Pharmacol. | |
dc.contributor.department | İstanbul Üniversitesi , , | |
dc.identifier.volume | 64 | |
dc.identifier.issue | 9 | |
dc.identifier.startpage | 889 | |
dc.identifier.endpage | 894 | |
dc.contributor.firstauthorID | 341872 | |